AI and smartphone videos could help parents spot seizures in newborns

NCT ID NCT07695623

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study aims to develop a machine learning tool that can predict which newborns are at high risk of having more seizures after leaving the hospital. Researchers will also create a mobile video education program for mothers of high-risk infants, teaching them how to recognize seizures, give emergency care, and manage medications. The study will test whether this education improves mothers' knowledge and reduces their anxiety compared to standard discharge instructions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mobile Video-Supported Education
What this could lead to
If successful, this approach could help identify infants at highest risk of seizure recurrence and provide parents with better tools to manage their baby's condition at home.
What could go wrong
This is a small, early-stage study (60 participants) focused on knowledge and anxiety, not on preventing seizures directly. The machine learning model may not be accurate enough for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The infant is classified as high risk according to the machine learning-based risk prediction model developed in the first phase of the study. * The infant is planned to be discharged home from the Neonatal Intensive Care Unit of Başakşehir Çam and Sakura City Hospital. * The mother is 18 years of age or older. * The mother is the primary caregiver responsible for the infant's care. * The mother is able to read, write, and communicate in Turkish. * The mother has access to a smartphone and active internet connection, either mobile data or Wi-Fi. * The mother is able to use a smartphone and basic communication applications such as WhatsApp. * The mother voluntarily agrees to participate in the study and signs the informed consent form. Exclusion Criteria: * The infant is transferred to another center before completion of the study process or during the discharge period. * The infant dies during the study period. * The mother has a diagnosed cognitive or psychiatric condition that may prevent her from understanding the educational materials or managing the study process. * The mother has a visual or hearing impairment that may prevent her from following the video content. * Significant connection problems occur during the qualitative interview process that prevent completion of the interview. * The mother is unable to access or complete the mobile video education within the first 72 hours after discharge due to technical reasons. * The mother wishes to withdraw from the study at any stage.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Seizure recurrence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.